Squarepoint’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.7M Buy
258,300
+62,900
+32% +$3.67M 0.02% 824
2025
Q4
$10.5M Sell
195,400
-78,100
-29% -$3.76M 0.01% 1054
2025
Q3
$12.3M Sell
273,500
-82,400
-23% -$3.85M 0.01% 974
2025
Q2
$16.5M Buy
355,900
+237,600
+201% +$11.7M 0.02% 860
2025
Q1
$7.22M Sell
118,300
-219,800
-65% -$12.8M 0.01% 1210
2024
Q4
$19.1M Buy
338,100
+94,800
+39% +$5.3M 0.02% 793
2024
Q3
$12.6M Sell
243,300
-103,900
-30% -$4.87M 0.02% 832
2024
Q2
$14.4M Sell
347,200
-804,200
-70% -$36M 0.02% 742
2024
Q1
$62.4M Buy
1,151,400
+845,500
+276% +$43.1M 0.11% 193
2023
Q4
$15.7M Sell
305,900
-139,400
-31% -$7.32M 0.03% 687
2023
Q3
$25.8M Buy
445,300
+280,200
+170% +$17.2M 0.06% 350
2023
Q2
$10.6M Buy
165,100
+6,300
+4% +$422K 0.03% 639
2023
Q1
$11M Buy
158,800
+51,800
+48% +$3.65M 0.04% 500
2022
Q4
$7.7M Buy
107,000
+19,400
+22% +$1.46M 0.03% 632
2022
Q3
$6.23M Buy
87,600
+4,900
+6% +$355K 0.03% 630
2022
Q2
$6.37M Buy
82,700
+5,100
+7% +$388K 0.04% 563
2022
Q1
$5.67M Buy
77,600
+71,900
+1,261% +$4.83M 0.02% 675
2021
Q4
$355K Buy
+5,700
New +$334K ﹤0.01% 2361
2021
Q3
Sell
-42,000
Closed -$2.81M 2932
2021
Q2
$2.81M Buy
+42,000
New +$2.74M 0.01% 996
2021
Q1
Sell
-22,200
Closed -$1.38M 3133
2020
Q4
$1.38M Buy
+22,200
New +$1.37M 0.01% 1143
2020
Q1
Sell
-3,600
Closed -$231K 1901
2019
Q4
$231K Sell
3,600
-1,900
-35% -$109K ﹤0.01% 2165
2019
Q3
$279K Buy
+5,500
New +$258K ﹤0.01% 1938

Other funds holding BMY

Squarepoint's BMY Position: Q1 2026 in Review

Squarepoint reduced its Bristol-Myers Squibb (BMY) stake by 89% in Q1 2026, selling an estimated $25.4M and leaving 54,134 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1817.

Squarepoint first reported a position in BMY in Q1 2015 and has held it in 39 quarters since. The position peaked at $184M in Q4 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Squarepoint held 54,134 shares of Bristol-Myers Squibb worth $3.28M as of Q1 2026.
  • Squarepoint sold 435,340 Bristol-Myers Squibb shares in Q1 2026, an estimated $25.4M.
  • Bristol-Myers Squibb made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1817 holding.
  • Squarepoint first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 39 quarters since.
  • Squarepoint's Bristol-Myers Squibb position peaked at $184M in Q4 2023.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.